Stock analysis for Arix Bioscience Plc (ARIX:London) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Arix | 46 follower su LinkedIn | ARIX is a web and mobile development group based out of New York’s Tech Valley region in Albany, NY. ARIX has prioritised 11 companies in the portfolio on which to focus its resources and expertise. Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement. The announcement can be accessed on Autolus' investor website at https://www.autolus.com/investor-relations and full text of the announcement from Autolus is contained below.

To listen to the webcast and view the accompanying slide presentation, please go to: https://www.autolus.com/investor-relations/news-and-events/events. ARIX minimises risk through its expert investment team and with portfolio diversification.

Robert Lyne Workshop Fitter at Hardy Spicer. Our structure as an open evergreen fund allows us to be flexible in our investment approach and also the possibility, when appropriate, to take a long-term perspective in our investments. Please ask to be joined into the Autolus Therapeutics call.

To listen to the webcast and view the accompanying slide presentation, please go to: https://www.autolus.com/investor-relations/news-and-events/events. Anyone who is unsure of their categorisation should consult their professional advisors. See others named Robert Lyne Add new skills with these courses. Non Executive Director Aura Biosciences. Arix Bioscience PLC: Autolus presents additional AUTO3 data in DLBCL 18-Sep-2020 / 08:57 GMT/BST The data support a best in class profile with a high level of complete remissions and a well tolerated safety profile," said Dr. "AUTO3 has a tolerable and very favorable safety profile when compared with approved CD19 CAR T therapies," said Dr, "It has a promising complete response rate of 64%, as demonstrated in the completed cohorts at the recommended Phase 2 dose range and, thus far, these complete remissions also appear durable.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. ARIX minimises risk through its expert investment team and with portfolio diversification. Management will host a conference call and webcast today at 8:00 am EDT/1:00 pm BST to discuss the ESMO data. Among all dose cohorts with a median follow up of 6 months, 93% of the patients who achieved a complete response did not relapse.". For further information, please visit www.arixbioscience.com, Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020, Conference call and webcast to be held Friday, September 18, 2020 at 8:00 am EDT / 1:00 pm BST. These have a number of important value inflection points - mostly clinical events - over the next 12-18 months. This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Hardman & Co Research: Realising the valuation disconnect. As of the data cut-off date of August 3, 2020, 35 patients in the ALEXANDER Phase 1/2 clinical trial of AUTO3 have been treated and were evaluable for safety. Among the 20 patients treated at a dose of >= 150 x 106 cells with pre-conditioning pembrolizumab on day minus 1 (D-1), which is the declared recommended Phase 2 dose (RP2D), one patient experienced >=Grade 3 NT (patient died due to disease progression and multiorgan failure). View recent trades and share price information for Arix Bioscience and other shares.